title: European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma.
abstract: Over the past two decades, not only treatment options, but also the diagnosis, staging, and risk assessment of multiple myeloma (MM), have undergone significant development, partially due to a deeper understanding of MM pathogenesis. Conventional cytogenetics and fluorescence in situ hybridization are routinely assessed in MM, and when combined with ISS stage may attain an even better predictive potential. In order to achieve even more effective and individualized therapies, one crucial goal is the identification of genes and gene combinations that predict for response or resistance to chemotherapy. High-dose chemotherapy with autologous stem cell transplant (SCT) still remains the standard therapy for younger patients, with novel agents now being included in both pre-transplant regimens and post-transplant consolidation/maintenance approaches. Similarly, novel agents are also being incorporated into allogeneic SCT for selected patients. In the treatment of elderly patients with MM, novel agents have been successfully incorporated into less intensive regimens, including melphalan/prednisone, low-dose dexamethasone, and cyclophosphamide/dexamethasone. While second-generation proteasome inhibitors are currently being intensively investigated, the subcutaneous administration of bortezomib, being equivalent to the established i.v. route, is now entering clinical practice. Supportive care remains a crucial aspect in the management of MM. The European Myeloma Network Trialist Group aims to address these contemporary aspects in MM.
authors.affiliation: Department of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany. monika.engelhardt@uniklinik-freiburg.de
authors.forename: Monika
authors.initials: M
authors.lastname: Engelhardt
authors.forename: Josefina
authors.initials: J
authors.lastname: Udi
authors.forename: Martina
authors.initials: M
authors.lastname: Kleber
authors.forename: Andrew
authors.initials: A
authors.lastname: Spencer
authors.forename: Alberto
authors.initials: A
authors.lastname: Rocci
authors.forename: Stefan
authors.initials: S
authors.lastname: Knop
authors.forename: Benedetto
authors.initials: B
authors.lastname: Bruno
authors.forename: Sara
authors.initials: S
authors.lastname: Bringhen
authors.forename: José A
authors.initials: JA
authors.lastname: Pérez-Simón
authors.forename: Sonja
authors.initials: S
authors.lastname: Zweegman
authors.forename: Christoph
authors.initials: C
authors.lastname: Driessen
authors.forename: Francesca
authors.initials: F
authors.lastname: Patriarca
authors.forename: Martin
authors.initials: M
authors.lastname: Gramatzki
authors.forename: Evangelos
authors.initials: E
authors.lastname: Terpos
authors.forename: Orhan
authors.initials: O
authors.lastname: Sezer
authors.forename: Martin
authors.initials: M
authors.lastname: Kropff
authors.forename: Christian
authors.initials: C
authors.lastname: Straka
authors.forename: Hans E
authors.initials: HE
authors.lastname: Johnsen
authors.forename: Anders
authors.initials: A
authors.lastname: Waage
authors.forename: Martin
authors.initials: M
authors.lastname: Boegsted
authors.forename: Henk
authors.initials: H
authors.lastname: Lokhorst
authors.forename: Roman
authors.initials: R
authors.lastname: Hájek
authors.forename: Gareth
authors.initials: G
authors.lastname: Morgan
authors.forename: Mario
authors.initials: M
authors.lastname: Boccadoro
authors.forename: Heinz
authors.initials: H
authors.lastname: Ludwig
authors.forename: Michele
authors.initials: M
authors.lastname: Cavo
authors.forename: Aaron
authors.initials: A
authors.lastname: Polliack
authors.forename: Pieter
authors.initials: P
authors.lastname: Sonneveld
authors.forename: Hermann
authors.initials: H
authors.lastname: Einsele
authors.forename: Antonio
authors.initials: A
authors.lastname: Palumbo
mesh_terms: D002986:Clinical Trials as Topic / Q000379:methods*; D003245:Consensus Statements as Topic; D005060:Europe; D005104:Expert Testimony; D006801:Humans; D007255:Information Services; D009101:Multiple Myeloma / Q000628:therapy*; D012107:Research Design; D016879:Salvage Therapy